Search

Photonics is an industry that has aroused Merck's curiosity for more than 30 years

Merck is accelerating development and production, and bringing resources and expertise to help identify effective and scalable solutions to the pandemic of Covid-19

Innovation present in Oryzon's programs in the field of epigenetics acknowledged. The company currently has 2 compounds in Phase II clinical studies, iadademstat and vafidemstat

This article will focus on the Systematic Scientific Literature Search and Review as part of the Clinical Evaluation process

This collaboration responds to the high quality of the research and scientific talent of the Hospital Nacional de Parapléjicos and the commitment of the science and technology company Merck to invest

Mirum expands potential opportunities across rare disease pipeline and Vivet will lead pre-clinical development of its two gene therapy programs for PFIC3 and PFIC2

Biotech company OWL Metabolomics develops non-invasive, early diagnosis products for obesity-related diseases

Goal is to explore effects of LSD1 inhibition on animal models of autism in Shank3 deficient mice models

In 2020, biologist Gema Malet Engra joined the biotechnology company Laminar Pharmaceuticals after a successful 15-year career in fundamental and applied research in Oncology at several international

PORTICO is a Phase IIb clinical trial with vafidemstat in Borderline Personality Disorder recruiting patients in Europe and the U.S and dedicated to independent assessment of reduction of agitation